New advancements for generating more accurate 2D and 3D models of the human brain

Complex in vitro models of the human brain are essential for developing next-generation therapeutics to treat neurodegenerative and neuroinflammatory diseases. To maximize the likelihood that work with in vitro models can be translated into the clinic, these models must meet requirements for throughput, consistency, and physiological relevance, while also being developed efficiently.

Currently, many available tools for generating 2D and 3D neuronal models do not satisfy these criteria, leading to protracted research timelines.

In this webinar, Dr. Will Bernard, Director of Cell Type Development at, and Dr. Martin Engel, Principal Scientist and Senior Business Development Manager at Inventia Life Sciences, will present data on tools and methods for the generation of functional, scalable 2D and 3D co-culture models of the human brain for disease research and drug discovery.

Key learning objectives

  • Explore newly published data showing how deterministically programmed iPSC-derived cells can be combined with the RASTRUM 3D bioprinter to generate scalable 3D co-culture models of the human brain
  • Examine new data showing how consistent, functional, human disease-relevant co and tri cultures can be generated using deterministically programmed cells
  • Understand how integrating cutting-edge developments in 3D cell culture technology and human iPSC-derived cell generation methodologies could increase the speed, repeatability and physiological relevance of your disease research or drug discovery workflows

Who should attend?

  • Researchers and research leaders with a keen interest in modelling the human brain in vitro.
  • Scientists involved in research and drug discovery for neurodegenerative and neurodevelopmental diseases
  • Anyone with an interest in the latest tools for in vitro drug screening in early-stage drug discovery

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.


Martin Engel, PhD
Martin Engel, PhD
Principal Scientist and Senior Business Development Manager, Inventia Life Sciences
Will Bernard, PhD
Will Bernard, PhD
Director, Cell Type Development,


Carrie Haslam
Carrie Haslam
Associate Editor, SelectScience